List of Figures
Figure 1: Pathophysiology of Hepatic Steatosis 13
Figure 2: Factors Contributing to Development of NASH from Steatotic Liver 15
Figure 3: Diagnostic Flow Chart for NASH 16
Figure 4: Stages of NASH Progression 19
Figure 5: Treatment Options in NASH (Potential Therapeutic Targets) 21
Figure 6: NASH Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for NASH Treatment, 2018 31
Figure 7: NASH Therapeutics Market, Global, Pipeline, 2018 33
Figure 8 NASH Therapeutics Market, Global, Pipeline by Molecular Target, 2018 34
Figure 9: NASH Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2018 35
Figure 10: NASH Therapeutics Market, APAC, Selonsertib Forecast ($m), 2023–2024 37
Figure 11: NASH Therapeutics Market, APAC, Elafibrinor Forecast ($m), 2023–2024 39
Figure 12: NASH Therapeutics Market, APAC, Saroglitazar Forecast ($m), 2020–2024 40
Figure 13: NASH Therapeutics Market, Comparative Efficacy and Safety Heatmap for Pipeline Products for NASH Treatment, 2018 46
Figure 14: NASH Therapeutics Market, Competitor Matrix for NASH Marketed and Pipeline Products, 2018 47
Figure 15: NASH Therapeutics Market, Global, Average Clinical Trial Failure Rate (%), 2017 49
Figure 16: NASH Therapeutics Market, Global, Clinical Trial Failure Rate by Molecule Type (%), 2007–2017 50
Figure 17: NASH Therapeutics Market, Global, Clinical Trial Failure Rate by Molecular Target (%), 2007–2017 51
Figure 18: NASH Therapeutics Market, Global, Clinical Trial Size per Product by Molecule Type, 2007–2017 52
Figure 19: NASH Therapeutics Market, Global, Clinical Trial Size per Product by Molecular Target, 2007–2017 53
Figure 20: NASH Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Type, 2007–2017 54
Figure 21: NASH Therapeutics Market, Global, Clinical Trial Size per Trial by Molecular Target, 2007–2017 55
Figure 22: NASH Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type, 2007–2017 56
Figure 23: NASH Therapeutics Market, Global, Clinical Trial Duration by Molecular Target, 2007–2017 57
Figure 24: NASH Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecule Type 58
Figure 25: NASH Therapeutics Market, Comparison of Average Trial Metrics by Phase and Molecular Target 58
Figure 26: NASH Therapeutics Market, APAC, Treatment Patterns (million), 2017–2024 60
Figure 27: NASH Therapeutics Market, APAC, Market Size ($m), 2017–2024 61
Figure 28: NASH Therapeutics Market, India, Treatment Usage Patterns (million), 2017–2024 62
Figure 29: NASH Therapeutics Market, India, Annual Cost of Therapy ($), 2017–2024 63
Figure 30: NASH Therapeutics Market, India, Market Size ($m), 2017–2024 64
Figure 31: NASH Therapeutics Market, China, Treatment Usage Patterns (millions), 2017–2024 65
Figure 32: NASH Therapeutics Market, China, Annual Cost of Therapy ($), 2017–2024 66
Figure 33: NASH Therapeutics Market, China, Market Size ($m), 2017–2024 67
Figure 34: NASH Therapeutics Market, Australia, Treatment Usage Patterns (million), 2017–2024 68
Figure 35: NASH Therapeutics Market, Australia, Annual Cost of Therapy ($), 2017–2024 70
Figure 36: NASH Therapeutics Market, Australia, Market Size ($m), 2017–2024 71
Figure 37: NASH Therapeutics Market, South Korea, Treatment Usage Patterns (million), 2017–2024 72
Figure 38: NASH Therapeutics Market, South Korea, Annual Cost of Therapy ($), 2017–2024 73
Figure 39: NASH Therapeutics Market, South Korea, Market Size ($m), 2017–2024 74
Figure 40: NASH Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2017–2024 75
Figure 41: NASH Therapeutics Market, Japan, Annual Cost of Therapy ($), 2017–2024 76
Figure 42: NASH Therapeutics Market, Japan, Market Size ($m), 2017–2024 77
Figure 43: NASH Therapeutics Market, Global, Licensing Deals by Region and Value, 2007–2018 81
Figure 44: NASH Therapeutics Market, Global, Number of Disclosed and Undisclosed Licensing Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2018 82
Figure 45: NASH Therapeutics Market, Global, Licensing Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007–2018 83
Figure 46: NASH Therapeutics Market, Global, Licensing Deals by Molecule Type and Stage of Development, 2007–2018 84
Figure 47: NASH Therapeutics Market, Global, Licensing Deals by Molecular Targets and Aggregate Deal Value ($), 2007–2018 85
Figure 48: NASH Therapeutics Market, Global, Co-development Deals by Region, 2007–2018 87
Figure 49: NASH Therapeutics Market, Global, Number of Disclosed and Undisclosed Co-development Deals by Year, Aggregate Deal Value and Aggregate Upfront Payment Value, 2007–2018 88
Figure 50: NASH Therapeutics Market, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2007–2018 89
Figure 51: NASH Therapeutics Market, Global, Co-development Deals by Molecule Type and Stage of Development, 2007–2018 90
Figure 52: NASH Therapeutics Market, Global, Co-development Deals by Molecular Target, 2007–2018 91